Beam Therapeutics Inc. Equity Securities, FV-NI, Gain (Loss)
Beam Therapeutics Inc. (BEAM) reported Equity Securities, FV-NI, Gain (Loss) of $338.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-04
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was $338.00K, a 92.34% decline year-over-year.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $16.00K.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was -$3.33M.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $4.94M.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for fiscal 2025 was $3.94M.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for fiscal 2024 was -$14.09M.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for fiscal 2023 was -$18.59M, a 192.04% decline from fiscal 2022.
- Beam Therapeutics Inc. equity securities, fv-ni, gain (loss) for fiscal 2022 was $20.20M, a 14.19% increase from fiscal 2021.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $338.00K 10-Q · filed 2026-08-04 | $354.00K 10-Q · filed 2026-08-04 | -$2.98M derived: sum of 3 quarters · filed 2026-08-04 | $1.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $16.00K 10-Q · filed 2026-05-07 | -$3.31M derived: sum of 2 quarters · filed 2026-05-07 | $1.62M derived: sum of 3 quarters · filed 2026-05-07 | $6.04M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.61M derived: sum of 2 quarters · filed 2026-02-24 | $6.02M derived: sum of 3 quarters · filed 2026-08-04 | $3.94M 10-K · filed 2026-02-24 |
| 2025-09-30 | $4.94M 10-Q · filed 2025-11-04 | $9.35M derived: sum of 2 quarters · filed 2026-08-04 | $7.27M 10-Q · filed 2025-11-04 | $6.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $4.42M 10-Q · filed 2026-08-04 | $2.33M 10-Q · filed 2026-08-04 | $1.24M derived: sum of 3 quarters · filed 2026-08-04 | -$820.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$2.08M 10-Q · filed 2026-05-07 | -$3.17M derived: sum of 2 quarters · filed 2026-05-07 | -$5.24M derived: sum of 3 quarters · filed 2026-05-07 | -$12.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$3.15M derived: sum of 2 quarters · filed 2026-02-24 | -$10.74M derived: sum of 3 quarters · filed 2026-02-24 | -$14.09M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$2.06M 10-Q · filed 2025-11-04 | -$9.65M derived: sum of 2 quarters · filed 2025-11-04 | -$13.00M 10-Q · filed 2025-11-04 | -$13.72M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$7.59M 10-Q · filed 2025-08-05 | -$10.94M 10-Q · filed 2025-08-05 | -$11.66M derived: sum of 3 quarters · filed 2026-02-24 | -$22.88M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$3.35M 10-Q · filed 2025-05-06 | -$4.08M derived: sum of 2 quarters · filed 2026-02-24 | -$15.30M derived: sum of 3 quarters · filed 2026-02-24 | -$9.15M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$722.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$11.94M derived: sum of 2 quarters · filed 2026-02-24 | -$5.79M derived: sum of 3 quarters · filed 2026-02-24 | -$18.59M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$11.22M 10-Q · filed 2024-11-05 | -$5.07M derived: sum of 2 quarters · filed 2024-11-05 | -$17.87M 10-Q · filed 2024-11-05 | $3.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $6.15M 10-Q · filed 2024-08-06 | -$6.65M 10-Q · filed 2024-08-06 | $14.93M derived: sum of 3 quarters · filed 2025-02-25 | $25.36M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$12.80M 10-Q · filed 2024-05-07 | $8.78M derived: sum of 2 quarters · filed 2025-02-25 | $19.21M derived: sum of 3 quarters · filed 2025-02-25 | $15.09M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $21.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $32.01M derived: sum of 2 quarters · filed 2025-02-25 | $27.89M derived: sum of 3 quarters · filed 2025-02-25 | $20.20M 10-K · filed 2025-02-25 |
| 2022-09-30 | $10.43M 10-Q · filed 2023-11-08 | $6.31M derived: sum of 2 quarters · filed 2023-11-08 | -$1.38M 10-Q · filed 2023-11-08 | -$5.65M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$4.12M 10-Q · filed 2023-08-08 | -$11.81M 10-Q · filed 2023-08-08 | -$16.08M derived: sum of 3 quarters · filed 2024-02-27 | -$20.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$7.68M 10-Q · filed 2023-05-10 | -$11.96M derived: sum of 2 quarters · filed 2024-02-27 | -$16.85M derived: sum of 3 quarters · filed 2024-02-27 | $8.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$9.16M derived: sum of 2 quarters · filed 2024-02-27 | $16.65M derived: sum of 3 quarters · filed 2024-02-27 | $17.69M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$4.89M 10-Q · filed 2022-11-07 | $20.92M derived: sum of 2 quarters · filed 2022-11-07 | $21.96M 10-Q · filed 2022-11-07 | $21.96M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $25.81M 10-Q · filed 2022-08-09 | $26.85M 10-Q · filed 2022-08-09 | $26.85M derived: sum of 3 quarters · filed 2023-02-28 | $26.85M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.04M 10-Q · filed 2022-05-09 | $1.04M derived: sum of 2 quarters · filed 2023-02-28 | $1.04M derived: sum of 3 quarters · filed 2023-02-28 | $1.56M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $517.00K derived: sum of 3 quarters · filed 2023-02-28 | $517.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $517.00K derived: sum of 2 quarters · filed 2021-11-08 | $517.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $517.00K 10-Q · filed 2021-08-10 | $517.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |